Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. - DiJoseph,J.F.; Dougher,M.M.; Kalyandrug,L.B.; Armellino,D.C.; Boghaert,E.R.; Hamann,P.R.; Moran,J.K.; Damle,N.K. (Clin Cancer Res, 2006)